Hyderabad: A Nashik-based cancer diagnostic research facility Datar Cancer Genetics has announced that US Food and Drug Administration (FDA) has granted ‘breakthrough designation’ for...
Combining homeopathy and biological growth factors, this bio-engineered treatment is a non-invasive, natural, Platelet Rich Plasma treatment and has also been approved by the FDA
Even 15 weeks after the first dose, eight of 10 people still had detectable germinal centers containing B cells targeting the virus.
The study, published in the journal Cell Reports, screened thousands of existing drugs and drug-like molecules for their ability to inhibit the replication of the Covid-19-causing coronavirus, SARS-CoV-2.
Amazon plans to use the real-time RT-PCR Test for detecting SARS-CoV-2 as part of the company's overall preparedness and response programme.
The authorisation allows the vaccine to be distributed in the US for use in individuals 18 years of age and older, the FDA said on Saturday.
“Many people wonder how we’ve done in less than a year what usually takes at least 4-5 years. It is through getting rid of the dead space," said Dr Peter Marks, director of CBER, FDA
China's Sinovac Biotech is the third vaccine maker that was given the green light by the FDA, Xinhua reported.
The European Union is under massive pressure to approve potential vaccines after Britain and the United States began rolling out a drug produced by Pfizer and BioNtech.
Health officials had feared the US Thanksgiving holiday in late November would lead to a fresh outbreak of the novel coronavirus after millions of Americans traveled to join friends and family.
With northern hemisphere countries hit by a pandemic winter surge, Britain this week became the first Western country to roll out the Pfizer-BioNTech vaccine.
Moderna also confirmed that it expects to have 20 million vaccine doses available in the US by the end of 2020.
The scientific head of the US operation to develop a vaccine, Moncef Slaoui said Monday that the green light would probably come in December.
The test is designed to be affordable and is intended to cost less than $50, according to the Lucira Health website.
The device targets adults 22 years or older who suffer from nightmare disorder or have nightmares from post-traumatic stress disorder (PTSD), the FDA said on Friday.
12Page 1 of 2
- Advertisement -